Showing results (291-300 of 319) with videos related to

Sort By:
Pageof 32
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|July 19, 2025
Clinical utility of thiopurine metabolite levels in monitoring patients with inflammatory bowel disease: A single-centre retrospective studyKhushboo G Upadhyay, Mihika B Dave, Devendra C Desai, et al.
Urology|May 6, 2023
Patients' Experiences With the Removal of a Ureteral Stent: Insights From In-depth Interviews With Participants in the USDRN STENTS Qualitative Cohort StudyCarrie Dombeck, Charles D Scales, Kevin McKenna, et al.
BJU International|June 28, 2025
Pain location after ureteroscopy differs based on sex and stone location: results from STENTSAndrew K Rabley, Naim M Maalouf, Hongqiu Yang, et al.
Blood Advances|August 14, 2020
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspectsJulie Kanter, Wally R Smith, Payal C Desai, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2014
Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)Lianhong Xu, Hongtao Liu, Allen Hong, et al.
BMC Nephrology|May 28, 2024
Using structured problem solving to promote fluid consumption in the prevention of urinary stones with hydration (PUSH) trialPeter P Reese, Salima Shah, Emily Funsten, et al.
Stem Cells Translational Medicine|September 14, 2021
Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's diseasePawan Kumar Gupta, Santanu Dutta, Sanjay Kala, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2018
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1Mukul R Jain, Jogeswar Mohapatra, Debdutta Bandhyopadhyay, et al.
Pharmacology Research & Perspectives|August 14, 2020
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancerKrishnarup Ghoshdastidar, Hoshang Patel, Hitesh Bhayani, et al.
Journal of Endourology|April 6, 2023
The Patient Voice: Stent Experiences After Ureteroscopy-Insights from In-Depth Interviews with Participants in the USDRN STENTS Nested Qualitative Cohort StudyAmy Corneli, Carrie Dombeck, Kevin McKenna, et al.
Pageof 32